Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04511650 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019
A Phase 2 study, sponsored by EyePoint Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04511650 is a Phase 2 study that was terminated before completion, run by EyePoint Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT04511650, a Phase 2 study, was terminated before completion, sponsored by EyePoint Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID) (every 8 hours \[Q8H\]), in hospitalized subjects with moderate to severe Coronavirus disease 2019 (COVID-19) receiving standard of care therapy. The study was planned to include 2 parts with Part 1 comprising the dose escalation period of the study and Part 2 comprising the proof-of-concept safety and efficacy period of the study.
Interventions
- DRUG Razuprotafib Subcutaneous Solution
- DRUG Placebo Subcutaneous Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-10-21 |
| Est. Completion | 2021-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04511650
The ClinicalTrials.gov registry entry for NCT04511650 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Razuprotafib Subcutaneous Solution is the first listed.
NCT04511650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04511650 about?
NCT04511650 is a clinical study titled "Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019". This was a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose escalation and proof-of-concept study to evaluate the safety and efficacy of razuprotafib, administered 3 times daily (TID) (every 8 hours \[Q8H\]), in hospitalized subjects with moderate to severe Co...
What is the current status of trial NCT04511650?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-10-21. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT04511650?
The interventions under investigation include: Razuprotafib Subcutaneous Solution (DRUG), Placebo Subcutaneous Solution (DRUG).
Who is sponsoring clinical trial NCT04511650?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.